Overview

Useful For
Evaluating the long-term control of blood glucose concentrations in diabetic patients
Diagnosing diabetes
Identifying patients at increased risk for diabetes (prediabetes)

Method Name
Ion-Exchange High-Performance Liquid Chromatography (HPLC)

NY State Available
Yes

Specimen

Specimen Type
Whole Blood EDTA

Specimen Required
Container/Tube: Lavender top (EDTA)

Specimen Volume: 3 mL

Collection Instructions: Send specimen in original tube.

Specimen Minimum Volume
2 mL

Reject Due To

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemolysis</td>
<td>NA</td>
</tr>
<tr>
<td>Lipemia</td>
<td>NA</td>
</tr>
<tr>
<td>Icterus</td>
<td>NA</td>
</tr>
<tr>
<td>Other</td>
<td>NA</td>
</tr>
</tbody>
</table>

Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole Blood EDTA</td>
<td>Refrigerated (preferred)</td>
<td>7 days</td>
</tr>
<tr>
<td></td>
<td>Frozen</td>
<td>7 days</td>
</tr>
<tr>
<td></td>
<td>Ambient</td>
<td>24 hours</td>
</tr>
</tbody>
</table>
Clinical and Interpretive

Clinical Information

Diabetes mellitus is a chronic disorder associated with disturbances in carbohydrate, fat, and protein metabolism characterized by hyperglycemia. It is one of the most prevalent diseases, affecting approximately 24 million individuals in the United States. Long-term treatment of the disease emphasizes control of blood glucose levels to prevent the acute complications of ketosis and hyperglycemia. In addition, long-term complications such as retinopathy, neuropathy, nephropathy, and cardiovascular disease can be minimized if blood glucose levels are effectively controlled.

Hemoglobin A1c (HbA1c) is a result of the nonenzymatic attachment of a hexose molecule to the N-terminal amino acid of the hemoglobin molecule. The attachment of the hexose molecule occurs continually over the entire life span of the erythrocyte and is dependent on blood glucose concentration and the duration of exposure of the erythrocyte to blood glucose. Therefore, the HbA1c level reflects the mean glucose concentration over the previous period (approximately 8-12 weeks, depending on the individual) and provides a much better indication of long-term glycemic control than blood and urinary glucose determinations. Diabetic patients with very high blood concentrations of glucose have from 2 to 3 times more HbA1c than normal individuals.

Diagnosis of diabetes includes 1 of the following:

- Fasting plasma glucose ≥ 126 mg/dL
- Symptoms of hyperglycemia and random plasma glucose ≥ 200 mg/dL
- Two-hour glucose ≥ 200 mg/dL during oral glucose tolerance test unless there is unequivocal hyperglycemia, confirmatory testing should be repeated on a different day

The American Diabetes Association (ADA), International Expert Committee (IEC), and the World Health Organization (WHO) recommend the use of HbA1c to diagnose diabetes, using a threshold of 6.5%. The threshold is based upon sensitivity and specificity data from several studies. Advantages to using HbA1c for diagnosis include:

- Provides an assessment of chronic hyperglycemia
- Assay standardization efforts from the National Glycohemoglobin Standardization Program (NGSP) have been largely successful and the accuracy of HbA1c is closely monitored by manufacturers and laboratories
- No fasting is necessary
- Intraindividual variability is very low (<2% variation)
- A single test could be used for both diagnosing and monitoring diabetes

When using HbA1c to diagnose diabetes, an elevated HbA1c should be confirmed with a repeat measurement, except in those individuals who are symptomatic and also have an increased plasma glucose greater than 200 mg/dL. Patients who have an HbA1c between 5.7 and 6.4 are considered at increased risk for developing diabetes in the future. (The terms prediabetes, impaired fasting glucose, and impaired glucose tolerance will eventually be phased out by the ADA to eliminate confusion.)

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's
metabolic control has remained continuously within the target range.

**Reference Values**

4.0-5.6%

<18 years: Hemoglobin A1c criteria for diagnosing diabetes have not been established for patients who are <18 years of age.

> or =18 years: Increased risk for diabetes (prediabetes):5.7-6.4%

Diabetes:> or =6.5%

Interpretive information based on Diagnosis and Classification of Diabetes Mellitus, American Diabetes Association.

**Interpretation**

Diagnosing diabetes American Diabetes Association (ADA)

- Hemoglobin A1c (HbA1c) > or =6.5%

Therapeutic goals for glycemic control (ADA)

- Adults:
  - Goal of therapy: <7.0% HbA1c
  - Action suggested: >8.0% HbA1c

- Pediatric patients:
  - Toddlers and preschoolers: <8.5% (but >7.5%)
  - School age (6-12 years): <8%
  - Adolescents and young adults (13-19 years): <7.5%

The ADA recommendations for clinical practice suggest maintaining a HbA1c value closer to normal yields improved microvascular outcomes for diabetics.(1) Target goals of less than 7% may be beneficial in patients such as those with short duration of diabetes, long life expectancy, and no significant cardiovascular disease. However, in patients with significant complications of diabetes, limited life expectancy, or extensive comorbid conditions, targeting a less than 7% goal may not be appropriate.

Since the HbA1c assay reflects long-term fluctuations in blood glucose concentration, a diabetic patient who has in recent weeks come under good control may still have a high concentration of HbA1c. The converse is true for a diabetic previously under good control who is now poorly controlled.

HbA1c results less than 4.0% are reported with the comment: "Falsely low HbA1c results may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present. Fructosamine may be used as an alternate measurement of glycemic control."

**Cautions**

The presence of hemoglobin variants can interfere with the measurement of HbA1c. The advantage of using ion
exchange chromatography methods is most variants that would affect HbA1c results can be detected from analysis of the chromatogram so inaccurate results are less likely to be reported.

Many common hemoglobin (Hb) variants (HbF <30%, heterozygous HbE, heterozygous HbD, heterozygous HbC, heterozygous HbS) do not interfere with this method. Other Hb variants that do show interference with this method include, but are not limited to Hb Camperdown, Hb Fukuoka, Hb Philadelphia, Hb Wayne, and Hb Raleigh.

In patients with rare homozygous and double heterozygous forms of abnormal Hb (eg, CC, SS, EE, SC), there is no HbA present; therefore, no hemoglobin A1c (HbA1c) value can be determined. If the specimen cannot be analyzed due to a homozygous variant or other interference, measurement of serum fructosamine may be helpful to monitor glycemic control. See FRUCT / Fructosamine, Serum.

Some hemoglobinopathies can be associated with reduced red blood cell (RBC) lifespan and any measured HbA1c concentration would not provide a true measurement of the patient's glycemic control and could lead to misinterpretation. In such situations, fructosamine should be used as an alternate measurement of glycemia and is recommended for monitoring these patients. See FRUCT / Fructosamine, Serum.

In cases of hemolytic anemia, the lifetime of erythrocytes is shortened and will result in decreased HBA1c results. This effect will depend upon the severity of the anemia. Specimens from patients with polycythemia or postsplenectomy may exhibit increased HBA1c values due to a somewhat longer lifespan of the RBCs. Caution should be exercised when interpreting the HbA1c results from patients with these conditions.

This assay is not useful in determining day-to-day glucose control and should not be used to replace daily home testing of blood glucose.

Clinical Reference
3. American Diabetes Association, Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes. Diabetes Care 2018; Jan;41:S1

Performance

Method Description
The D-100 HbA1c test utilizes principles of ion-exchange high-performance liquid chromatography (HPLC). The samples are automatically diluted on the D-100 and injected into the analytical cartridge. The D-100 delivers a programmed buffer gradient of increasing ionic strength to the cartridge, where the hemoglobins are separated based on their ionic interactions with the cartridge material. The separated hemoglobins then pass through the flowcell, where changes in the absorbance at 415 nm are measured. The D-100 software collects raw data from
each analysis and calculates HbA1c values based on a bilevel calibration curve. The HbA1c area is calculated using an exponentially modified Gaussian (EMG) algorithm. A sample report and a chromatogram are generated for each sample. (Instruction Manual: Bio-Rad D-100 HbA1c Instructions For Use, LB0002870revA, Hercules, CA, 2014)

PDF Report
No

Day(s) and Time(s) Test Performed
Monday through Sunday; Continuously

Analytic Time
Same day/1 day

Maximum Laboratory Time
1 day

Specimen Retention Time
3 days

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer’s instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information
83036

LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBA1C</td>
<td>Hemoglobin A1c, B</td>
<td>4548-4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBA1C</td>
<td>Hemoglobin A1c, B</td>
<td>4548-4</td>
</tr>
</tbody>
</table>